Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD [Yahoo! Finance]
lululemon athletica inc. (LULU)
Last lululemon athletica inc. earnings: 3/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.lululemon.com
Company Research
Source: Yahoo! Finance
- Lead program, EPI-321, is the first clinical application of epigenetic modulation in neuromuscular diseases, with a first-in-human trial in New Zealand to commence in 2025 as part of a broader global clinical strategy SOUTH SAN FRANCISCO, Calif., March 26, 2025 BUSINESS WIRE Epicrispr Biotechnologies , a biotechnology company focused on developing curative therapies, today announced it has secured $68 million in the first close of its Series B financing. The proceeds will support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease. The Series B financing was led by Ally Bridge Group, with participation from SOLVE FSHD, the venture philanthropy organization founded by Chip Wilson, founder of Lululemon Athletica and FSHD patient, along with other new and existing investors. The financing will support Epicrispr's upcoming clinical trial of EPI-321, as well as continued a
Show less
Read more
Impact Snapshot
Event Time:
LULU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LULU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LULU alerts
High impacting lululemon athletica inc. news events
Weekly update
A roundup of the hottest topics
LULU
News
- Is LULU Stock a Buy After the CEO Announced His Resignation? [Yahoo! Finance]Yahoo! Finance
- 3 Must-Know Facts About Lululemon Before You Buy the Stock [Yahoo! Finance]Yahoo! Finance
- Lululemon (LULU) Stock in 2026: What Investors Need to Watch [Yahoo! Finance]Yahoo! Finance
- Taking Stock of Lululemon (LULU)'s Valuation After Elliott's Activist Stake and Global Expansion Push [Yahoo! Finance]Yahoo! Finance
- Elliott Takes $1 Billion Stake in Lululemon, Swaying CEO Search [Yahoo! Finance]Yahoo! Finance
LULU
Earnings
- 12/11/25 - Beat
LULU
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/17/25 - Form 4
- LULU's page on the SEC website